Projects per year
- 5 Active
Phase 3, Randomized, Open-Label, Multicenter Study of ARV-471 (PF-07850327) plus Palbociclib versus Letrozole plus Palbociclib for the Treatment of Participants with Estrogen Receptor-Positive, HER2-Negative Breast Cancer Who Have Not Received Any Prior Systemic Anti-Cancer Treatment for Advanced Disease (VERITAC-3)
20/09/23 → 19/09/25
A Phase 3, Randomized, Open-Label, Multicenter Trial of ARV-471 (PF-07850327) vs Fulvestrant in Participants with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer Whose Disease Progressed After Prior Endocrine Based Treatment for Advanced Disease (VERITAC-2)
23/05/23 → 23/05/25
A phase 3, randomised, double-blind study of Trilaciclib or placebo in patients receiving first or second line Gemcitabine and Carboplatin chemotherapy for locally advanced unresectable or metastatic triple-negative breast cancer [G1T28-208] [PRESERVE 2].
Antill, Y. & Lai, L. H.
25/11/21 → 31/12/24
A Phase 1b/III study of Ipatasertib plus Palbociclib and Fulvestrant versus placebo plus Palbociclib and Fulvestrant in hormone receptor positive and Her2 negative locally advanced unresectable or metastatic breast cancer [Ipatunity150] [CO41012]
Antill, Y., Baker, E. & Thompson, K.
13/02/20 → 31/12/25